Absolute Bioavailability of Ceftriaxone after Intramuscular Administration to Healthy Volunteers

Chemotherapy ◽  
1983 ◽  
Vol 29 (3) ◽  
pp. 157-162 ◽  
Author(s):  
R. Delsignore ◽  
C.M. Baroni ◽  
G. Crotti ◽  
F. Mineo ◽  
U. Butturini ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Intramuscular Administration ◽  
Absolute Bioavailability

Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers

1996 ◽  
Vol 51 (2) ◽  
pp. 183-187 ◽  
Author(s):  
R. Koytchev ◽  
R.-G. Alken ◽  
G. McKay ◽  
T. Katzarov
Keyword(s):  
Healthy Volunteers ◽  
Slow Release ◽  
Absolute Bioavailability

INVESTIGATION OF DOSE PROPORTIONALITY AND ABSOLUTE BIOAVAILABILITY OF BROFAROMINE IN HEALTHY VOLUNTEERS

1992 ◽  
Vol 15 ◽  
pp. 430B ◽  
Author(s):  
K. H. Antonin ◽  
K. Kucher ◽  
L. Fuchs ◽  
P. R. Bieck ◽  
E. Schmidt
Keyword(s):  
Healthy Volunteers ◽  
Dose Proportionality ◽  
Absolute Bioavailability

Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration

2006 ◽  
Vol 62 (7) ◽  
pp. 511-512 ◽  
Author(s):  
Petra A. Thürmann ◽  
Jacek Szymanski ◽  
Steffen Haffner ◽  
Ute Tenter ◽  
Frank Grieger ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Intramuscular Administration

scholarly journals Absolute Bioavailability and Intracellular Pharmacokinetics of Azithromycin in Patients with Cystic Fibrosis

2005 ◽  
Vol 49 (12) ◽  
pp. 5013-5017 ◽  
Author(s):  
Paul Beringer ◽  
Kitty My Tu Huynh ◽  
Jane Kriengkauykiat ◽  
Luke Bi ◽  
Nils Hoem ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Healthy Volunteers ◽  
Drug Concentration ◽  
Elimination Rate ◽  
Pancreatic Enzymes ◽  
Absolute Bioavailability ◽  
Peripheral Compartment ◽  
Serum Drug Concentration ◽  
Open Label ◽  
Maximum Serum

ABSTRACT Chronic pulmonary infections with Pseudomonas aeruginosa are the primary cause of morbidity and mortality in patients with cystic fibrosis (CF). The macrolide antibiotics exhibit immunomodulatory and antivirulence activity. Clinical trials with azithromycin in CF have demonstrated significant improvements in pulmonary function and decreased hospitalizations. The purpose of this study was to compare the pharmacokinetics (PK) of azithromycin in patients with CF and controls. The study was conducted as an open-label, parallel, two-period crossover study involving 12 healthy volunteers and 12 patients with CF. Period 1 examined the serum PK following a single oral and intravenous dose, while period 2 examined the intracellular PK following multiple-dose oral administration. CF subjects differed significantly from controls based on weight (53.1 versus 71.0 kg; P < 0.01) and body mass index (19.7 versus 23.2; P < 0.01), respectively. Ninety-two percent of CF patients were pancreatic insufficient and were receiving pancreatic enzymes. The rate (time to reach maximum serum drug concentration, 3.0 versus 3.0 h; P = 0.78) and extent of absorption (absolute bioavailability, 34.2 versus 42.8%; P = 0.37) were similar in patients with CF and controls, respectively. Distribution to the tissues (rate of drug transfer from the central to the peripheral compartment, 1.22 versus 0.759 h−1; P = 0.03) and elimination (rate of elimination from the central compartment, 0.693 versus 0.492 h−1; P < 0.01) were more rapid in the healthy volunteers than in the CF subjects, respectively. Mononuclear cell concentrations (15.2 ± 6.0 mg/liter) far exceeded the maximum serum drug concentration (∼50-fold), demonstrating significant intracellular accumulation. These results indicate no alteration in dosage of azithromycin is necessary in patients with CF taking pancreatic enzymes.

Sign in / Sign up

Export Citation Format

Share Document